allogen
hematopoiet
stem
cell
transplant
allohsct
becom
wide
use
modal
therapi
varieti
malign
nonmalign
diseas
mani
advanc
made
field
infect
remain
one
sever
frequent
encount
complic
hsct
chapter
review
defect
host
defens
import
risk
factor
predispos
allohsct
recipi
infect
major
categori
infect
time
cours
follow
transplant
prevent
strategi
sever
defect
host
defens
subsequ
risk
infect
influenc
complex
interact
sever
factor
particularli
salient
underli
ill
patient
condit
regimen
graft
close
match
type
transplant
presenc
graftversushost
diseas
gvhd
immedi
local
remot
epidemiolog
factor
also
import
time
impair
host
defens
infecti
risk
allohsct
recipi
outlin
fig
infect
risk
much
impact
diseas
patient
transplant
also
presenc
preced
infect
acut
leukemia
exampl
predispos
neutropenia
defect
innat
immun
profound
neutropenia
cellsmm
greater
durat
consid
strong
risk
factor
bacteri
invas
fungal
infect
addit
neutropenia
factor
increas
risk
invas
aspergillosi
includ
advanc
refractori
acut
myelogen
leukemia
highrisk
myelodysplast
syndrom
chronic
neutropenia
prior
chemotherapi
iron
overload
secondari
repeat
peripher
blood
transfus
prior
fungal
infect
antileukem
agent
shown
diminish
antibodi
respons
primari
antigen
therebi
increas
suscept
bacteri
pathogen
even
absenc
neutropenia
underli
diseas
primari
immunodefici
exampl
may
predispos
progress
reactiv
anteced
infect
individu
myelodysplast
syndrom
neutropen
time
transplant
increas
risk
infect
mortal
addit
innat
immun
defect
increas
age
wane
cellular
immun
organ
dysfunct
fragil
skin
prior
antibiot
exposur
may
contribut
progress
preexist
infect
includ
aspergillosi
well
risk
new
infect
posttranspl
period
presenc
infect
immedi
preced
allohsct
also
impact
infecti
risk
posttranspl
period
individu
schedul
undergo
allohsct
activ
infect
treat
prior
transplant
whenev
possibl
time
allohsct
follow
initi
antibiot
activ
infect
made
case
case
basi
experienc
practition
prior
transplant
prospect
recipi
must
condit
allow
engraft
transplant
goal
condit
twofold
suppress
recipi
immun
system
particularli
tcell
arm
order
prevent
reject
graft
elimin
tumor
mani
regimen
myeloabl
employ
total
bodi
irradi
cytotox
chemotherapi
result
profound
prolong
neutropenia
mucos
potenti
organ
toxic
recipi
condit
highli
suscept
earli
infect
sepsi
less
intens
regimen
increasingli
use
vulner
older
patient
may
result
minim
neutropenia
mucos
correspondingli
lower
risk
infect
howev
recipi
reducedintens
condit
regimen
may
experi
prolong
neutropenia
engraft
fail
close
human
leukocyt
antigen
hla
match
dictat
likelihood
sever
gvhd
well
intens
immunosuppress
regimen
variou
degre
match
includ
follow
donor
may
hlamatch
sibl
twin
hlamatch
unrel
haploident
donor
recipi
share
one
complet
haplotyp
partial
match
latter
two
categori
often
necessit
intens
immunosuppress
regimen
prevent
gvhd
sourc
stem
cell
also
impact
risk
infect
bone
marrow
transplant
recipi
prolong
period
neutropenia
higher
risk
earli
infect
lower
risk
gvhd
peripher
stem
cell
mobil
granulocyt
colonystimul
factor
cord
blood
cell
contrast
typic
obtain
unrel
donor
confer
much
lower
gvhd
occur
donor
tcell
attack
recipi
tissu
consequ
either
tcell
ablat
graft
prior
transplant
administr
immunosuppress
drug
transplant
unmanipul
bone
marrow
peripher
stem
cell
use
kg
cell
administ
ex
vivo
pretreat
graft
may
produc
reduct
cell
transplant
decreas
potenti
risk
sever
gvhd
howev
result
prolong
tcell
immunodefici
patient
must
walk
immunologicalinfect
tightrop
mani
month
untreat
graft
transplant
one
varieti
immunosuppress
regimen
may
given
exampl
sirolimu
calcineurin
inhibitor
tacrolimu
appear
regimen
pose
lower
infect
risk
pretranspl
tcell
ablat
sirolimu
therapi
also
associ
reduc
risk
cytomegaloviru
cmv
infect
gvhd
classifi
acut
onset
prior
posttranspl
day
chronic
onset
day
acut
diseas
may
persist
chronic
period
case
term
progress
gvhd
may
respond
treatment
go
remiss
may
also
reactiv
later
date
acut
diseas
character
secretori
diarrhea
hepat
skin
rash
categor
accord
sever
grade
pose
increas
risk
mortal
corticosteroid
mainstay
therapi
intens
immunosuppress
associ
condit
enhanc
treatment
combin
disrupt
barrier
defens
especi
intestin
place
patient
great
risk
infect
cmv
infect
common
viral
bacteri
fungal
infect
aspergillosi
chronic
gvhd
humor
defect
function
hyposplen
markedli
suppress
cellular
immun
sever
pneumococc
dissemin
fungal
cmv
infect
frequent
seen
context
infect
even
problemat
steroidrefractori
diseas
necessit
use
potent
immunosuppress
regimen
cyclophosphamid
alemtuzumab
antithymocyt
globulin
situat
human
adenoviru
dissemin
fungal
nocardi
infect
well
posttranspl
lymphoprolif
diseas
ptld
may
occur
three
period
immunodefici
occur
follow
hematopoiet
stem
cell
transplant
preengraft
day
earli
postengraft
day
late
postengraft
day
immun
suppress
take
place
period
convey
particular
risk
infect
drive
use
standard
prophylaxi
follow
transplant
fig
preengraft
period
associ
three
major
risk
factor
infect
prolong
neutropenia
disrupt
mucos
barrier
relat
prepar
chemotherapeut
regimen
presenc
frequent
util
central
venou
access
combin
effect
neutropenia
mucos
contribut
high
risk
reactiv
hsv
seroposit
patient
prompt
standard
use
acyclovir
period
factor
also
predispos
candidemia
earlyonset
aspergillosi
prophylact
antifung
use
preengraft
period
fluconazol
prophylaxi
link
increas
risk
nonalbican
candid
infect
particularli
due
c
glabrata
c
krusei
voriconazol
prophylaxi
also
associ
increas
risk
zygomycosi
set
addit
mechan
disrupt
skin
use
prophylact
antibiot
target
toward
gut
flora
increas
risk
bloodstream
infect
gramposit
flora
particularli
viridian
group
streptococci
coagulaseneg
staphylococci
earli
postengraft
period
extend
time
neutrophil
recoveri
approxim
day
posttransplant
day
notabl
band
tlymphocyt
dysfunct
set
allohsct
recipi
impact
immunodefici
mediat
gvhd
cmv
infect
well
treatment
cellmedi
immun
dysfunct
contribut
increas
risk
viral
infect
includ
cmv
adenoviru
varicella
zoster
viru
vzv
epsteinbarr
viru
ebv
relat
ptld
well
lateonset
aspergillosi
pneumocysti
jirovecii
late
postengraft
period
extend
day
normal
immun
function
regain
immun
function
gener
return
within
month
transplant
durat
late
postengraft
period
may
extend
allohsct
recipi
owe
chronic
gvhd
manag
time
ongo
humer
cellmedi
immun
dysfunct
contribut
risk
infect
vzv
cmv
lateonset
aspergillosi
infect
encapsul
bacteria
microbiolog
bacteri
infect
allohsct
patient
evolv
time
past
decad
greatli
influenc
widespread
use
fluoroquinolon
prophylaxi
increas
preval
clostridium
difficil
infect
evolut
condit
regimen
transplant
patient
increas
risk
bacteri
infect
remaind
lifetim
preengraft
period
bacteremia
occur
patient
tabl
list
common
infect
pathogen
particular
risk
clinic
manifest
main
sourc
bacteremia
oral
gastrointestin
mucos
respiratori
tract
presenc
central
venou
cathet
infect
organ
commonli
gramposit
cocci
streptococcu
viridan
enterococci
varieti
ferment
nonfer
gramneg
rod
enterococci
increasingli
resist
vancomycin
strain
associ
wors
prognosi
vancomycinsensit
strain
recent
studi
also
report
increas
infect
due
multidrug
resist
mdr
gramneg
rod
pseudomona
aeruginosa
carbapenemaseproduc
klebsiella
pneumonia
isol
resist
bacteria
associ
use
fluoroquinolon
prophylaxi
thirdgener
cephalosporin
sever
report
infect
carri
high
mortal
often
relaps
gastrointestin
infect
promin
period
necrot
enterocol
typhliti
may
occur
sever
neutropen
patient
serv
sourc
bacteremia
sepsi
clostridium
difficil
coliti
common
occur
allogen
transplant
patient
versu
autolog
patient
preengraft
period
extens
antibiot
exposur
mucos
damag
intens
chemotherapi
multipl
prior
hospit
contributori
clostridium
difficil
link
levofloxacin
frequent
given
bacteri
prophylaxi
patient
hypervirul
strain
clostridium
difficil
includ
epidem
north
american
pulsefield
gel
electrophoresi
type
ribotyp
iii
strain
specif
associ
moxifloxacin
member
fluoroquinolon
class
associ
clostridium
difficil
coliti
subsequ
gvhd
also
report
coliti
may
sever
often
relaps
may
also
serv
sourc
secondari
bloodstream
infect
risk
infect
bacteremia
neutropen
preengraft
period
reduc
use
prophylact
antibiot
gener
fluoroquinolon
usual
levofloxacin
prefer
agent
prophylaxi
start
stem
cell
infus
continu
resolut
neutropenia
initi
antibiot
therapi
neutropen
fever
sever
metaanalys
demonstr
decreas
infectionassoci
morbid
mortal
well
cost
benefit
use
prophylact
antibacteri
agent
howev
increas
risk
select
resist
bacteria
clostridium
difficileassoci
diseas
earli
period
engraft
risk
bacteri
infect
bacteremia
reduc
ongo
risk
increas
gener
debil
presenc
renal
hepat
dysfunct
presenc
gvhd
central
venou
line
often
sourc
patient
time
receiv
antibiot
cours
make
like
infect
resist
pathogen
staphylococci
enterococci
often
vancomycin
resist
nonfer
gramneg
stenotrophomona
maltophilia
acinetobact
frequent
pathogen
virtu
tcell
immunosuppress
patient
also
particularli
suscept
listeria
legionella
expos
late
period
follow
engraft
main
predispos
factor
infect
presenc
gvhd
mani
patient
bcell
dysfunct
function
asplen
thu
vulner
seriou
infect
encapsul
bacteria
notabl
streptococcu
pneumonia
pneumonia
usual
sourc
patient
hypogammaglobulinem
increas
risk
less
common
infect
due
mycobacteria
nocardia
case
report
suggest
global
incid
nontubercul
mycobacteri
infect
allohsct
recipi
rang
tuberculosi
patient
popul
howev
rang
unit
state
high
taiwan
system
nocardiosi
rare
one
center
report
cumul
incid
case
observ
patient
extens
chronic
gvhd
prevent
strategi
includ
vaccin
heptaval
conjug
pneumococc
vaccin
month
postengraft
patient
immunogen
vaccin
howev
appear
relat
immun
reconstitut
particularli
allohsct
recipi
age
popul
improv
vaccin
respons
associ
igg
mgdl
phytohemagglutinin
within
lower
limit
normal
patient
activ
gvhd
also
receiv
antibiot
prophylaxi
aim
pneumococcu
penicillin
v
usual
suffic
trimethoprimsulfamethoxazol
doxycyclin
may
also
consid
depend
local
resist
pattern
patient
sever
hypogammaglobulinem
mg
igg
regular
infus
intraven
immunoglobulin
ivig
consid
meticul
care
central
venou
cathet
mandatori
clostridium
difficil
occur
time
though
risk
greatest
period
hospit
risk
increas
proport
antibiot
exposur
especi
perhap
fluoroquinolon
presenc
gvhd
cours
nosocomi
risk
eg
outbreak
relaps
common
treatment
viral
pathogen
signific
sourc
morbid
mortal
allohsct
allohsct
recipi
affect
wide
rang
virus
either
primari
infect
donorderiv
infect
reactiv
latent
viru
cmv
continu
one
import
pathogen
group
estim
popul
unit
state
latent
infect
cmv
place
world
includ
develop
nation
preval
even
higher
prior
widespread
use
anticmv
prophylaxi
approxim
seroposit
allohsct
recipi
develop
cmv
reactiv
usual
first
month
transplant
despit
prophylaxi
either
ganciclovir
valganciclovir
incid
cmv
reactiv
rang
episod
increasingli
occur
prophylaxi
finish
late
cmv
approxim
allohsct
recipi
cmv
reactiv
develop
diseas
clinic
manifest
cmv
diseas
variabl
includ
interstiti
pneumonia
enter
hepat
retin
enceph
cmv
syndrom
includ
cytopenia
fever
cmvrelat
mortal
averag
high
case
sever
pneumonia
addit
direct
endorgan
effect
cmv
diseas
also
associ
increas
bacteri
fungal
viral
infect
classic
import
risk
factor
cmv
reactiv
serostatu
recipi
donor
cmvinfect
seroposit
patient
receiv
graft
seroneg
donor
consid
highest
risk
addit
risk
factor
includ
total
bodi
radiat
condit
phase
develop
acut
chronic
gvhd
tcelldeplet
therapi
steroid
dose
greater
mgkg
per
day
use
mismatch
unrel
donor
diagnosi
cmv
diseas
remain
clinic
challeng
given
vari
nonspecif
present
although
pcr
analysi
cmv
dna
serum
becom
mainstay
diagnosi
absolut
cutoff
viremia
exist
differenti
infect
diseas
presenc
viremia
automat
indic
diseas
although
studi
shown
likelihood
diseas
high
level
copiesml
found
convers
diseas
alway
correl
viremia
especi
case
gastrointestin
involv
introduct
intern
unit
better
studi
correl
diseas
viremia
possibl
futur
intraven
ganciclovir
firstlin
therapi
cmv
diseas
allohsct
recipi
nonsever
case
includ
asymptomat
viremia
oral
valganciclovir
use
due
toxic
foscarnet
cidofovir
consid
secondlin
drug
reserv
treatment
failur
due
gcv
resist
situat
gcv
toler
recommend
continu
treatment
day
cmv
dna
longer
detect
serum
follow
month
mainten
therapi
cmv
immunoglobulin
studi
gener
reserv
sever
case
especi
pneumonia
lack
respons
antivir
therapi
recent
studi
suggest
cmvspecif
tcell
administr
effect
prophylaxi
treatment
cmv
although
riskstratifi
prophylaxi
oral
valganciclovir
effect
problem
toxic
especi
bone
marrow
suppress
preclud
standard
approach
altern
approach
involv
frequent
serum
cmv
pcr
monitor
initi
treatment
viremia
detect
preemptiv
approach
usual
logist
difficult
lead
higher
rate
cmv
reactiv
elus
goal
mani
decad
search
vaccin
recent
shown
promis
result
around
glycoprotein
b
phosphoprotein
epitop
unit
state
worldwid
estim
almost
adult
demonstr
past
infect
ebv
spectrum
ebvrel
diseas
includ
asymptomat
viremia
viral
syndrom
fever
neutropenia
oral
hairi
leukoplakia
rare
meningoenceph
importantli
ebv
also
associ
case
ptld
allohsct
recipi
ptld
usual
occur
first
year
transplant
aris
ebvspecif
tlymphocyt
deplet
allow
uncheck
prolifer
donorderiv
monoclon
polyclon
b
cell
spectrum
ptld
includ
extranod
lymphocyt
infiltr
highgrad
bcell
lymphoma
vari
indol
fulmin
present
although
overal
incid
ebvrel
ptld
popul
approxim
children
mortal
high
risk
factor
includ
age
recipi
mismatch
match
unrel
tcelldeplet
transplant
acut
chronic
gvhd
use
tcelldeplet
agent
thymoglobulin
alemtuzumab
treatment
option
rang
reduc
immunosuppress
chemotherapeut
agent
rituximab
chop
antivir
agent
limit
role
treatment
prevent
ebvptld
given
persist
increas
ebv
viremia
usual
preced
ptld
preemptiv
treatment
rituximab
may
reduc
risk
progress
ptld
us
adult
latent
infect
allohsct
recipi
receiv
antivir
prophylaxi
rate
reactiv
high
often
occur
earlier
week
postengraft
herpesvirus
clinic
manifest
commonli
includ
orallabi
lesion
esophag
vari
caus
bone
marrow
suppress
kerat
pneumonia
hepat
well
meningoenceph
hand
less
frequent
usual
involv
perin
lesion
recurr
episod
either
infect
may
warrant
suppress
therapi
similar
hsv
reactiv
common
caus
vzvrelat
diseas
allohsct
occur
patient
first
year
transplant
sinc
antihsv
cmv
prophylaxi
effect
vzv
reactiv
usual
occur
prophylaxi
stop
although
breakthrough
also
occur
gvhd
major
risk
factor
vzv
reactiv
clinic
manifest
includ
either
classic
multidermatom
shingl
lesion
usual
take
longer
heal
immunocompet
patient
dissemin
vzv
rare
sever
occurr
involv
lung
liver
cn
reactiv
common
earli
post
allohsct
rang
patient
first
month
vast
major
case
rang
asymptomat
viremia
fever
transient
marrow
suppress
patient
infrequ
develop
sever
diseas
includ
enceph
hepat
pneumon
posttranspl
acut
limbic
enceph
form
cn
diseas
allohsct
recipi
relat
reactiv
addit
direct
effect
viremia
found
increas
delay
engraft
gvhd
well
predispos
patient
cmv
ebv
reactiv
risk
factor
reactiv
includ
cord
blood
transplant
well
hla
mismatch
ganciclovir
activ
use
treatment
screen
prevent
measur
develop
viremia
also
common
occurr
associ
posthsct
diseas
well
document
time
report
cn
diseas
associ
viru
report
transmit
seroneg
recipi
clinic
manifest
viremia
also
well
document
time
although
may
possibl
relat
fever
rash
mild
hepat
bone
marrow
aplasia
unlik
solid
organ
transplant
case
kaposi
sarcoma
rare
besid
reactiv
latent
infect
allohsct
recipi
suscept
transmiss
adv
via
stem
cell
graft
well
primari
acquisit
serotyp
allohsct
recipi
affect
adv
reactiv
children
year
age
reactiv
usual
occur
day
posttranspl
besid
young
age
risk
factor
reactiv
includ
sever
gvhd
highdos
steroid
well
use
unrel
cord
blood
recipi
adv
viremia
approxim
develop
diseas
rang
viral
syndrom
fever
elev
liver
enzym
pancytopenia
pneumon
nephropathi
hemorrhag
cystiti
coliti
myocard
cn
diseas
mortal
set
adv
diseas
estim
around
diagnosi
usual
combin
high
clinic
suspicion
serum
adv
quantit
pcr
histolog
treatment
well
defin
usual
consist
reduc
immunosuppress
cidofovir
high
incid
nephrotox
prevent
measur
also
well
defin
continu
improv
detect
techniqu
respiratori
viral
pathogen
increasingli
recogn
signific
sourc
morbid
mortal
among
recipi
allohsct
includ
among
other
influenza
parainfluenza
rsv
human
metapneumoviru
well
multipl
strain
rhinovirus
coronavirus
bocavirus
commun
nosocomi
outbreak
respons
major
infect
rate
respiratori
viral
infect
among
allohsct
recipi
undergo
season
variat
much
like
gener
popul
estim
vari
studi
shown
influenza
b
parainfluenza
rsv
common
caus
viral
respiratori
infect
risk
factor
includ
gvhd
lymphopenia
presenc
children
younger
year
age
home
diagnosi
involv
clinic
suspicion
rtpcr
mortal
variabl
usual
associ
complic
respiratori
failur
bacteri
fungal
superinfect
prevent
measur
includ
vaccin
hand
wash
isol
measur
set
outbreak
besid
antiinfluenza
drug
antivir
therapi
respiratori
virus
remain
larg
unproven
main
risk
hepat
b
viru
reactiv
previous
resolv
infect
occur
case
prophylaxi
institut
among
reactiv
liver
failur
rare
complic
recommend
recipi
donor
check
hepat
b
serolog
prior
hsct
appropri
therapeut
prophylact
measur
taken
although
commonli
affect
renal
transplant
recipi
bk
viru
reactiv
also
describ
caus
hemorrhag
cystiti
nephropathi
allohsct
recipi
jcvrelat
progress
multifoc
leukoencephalopathi
pml
rare
welldescrib
complic
allohsct
recipi
dismal
prognosi
invas
fungal
infect
ifi
major
caus
morbid
mortal
among
hsct
recipi
individu
undergo
allohsct
higher
risk
develop
ifi
compar
recipi
autolog
graft
larg
owe
delay
engraft
gvhd
epidemiolog
ifi
hsct
recipi
remain
dynam
sinc
decreas
incid
invas
candidiasi
among
hsct
recipi
due
widespread
use
fluconazol
prophylaxi
howev
ifi
due
aspergillu
filament
mold
remain
signific
concern
candida
candida
speci
commonli
inhabit
skin
mucosa
gastrointestin
tract
disrupt
integr
either
mucos
barrier
lead
invas
candidiasi
set
allohsct
invas
candidiasi
typic
result
mucos
gastrointestin
tract
incur
condit
addit
risk
factor
invas
candidiasi
includ
hla
mismatch
recipi
age
prolong
neutropenia
gvhd
gastrointestin
tract
colon
cmv
diseas
earli
two
larg
trial
demonstr
signific
decreas
candidiasi
use
fluconazol
prophylaxi
administr
day
posttranspl
later
shown
significantli
reduc
mortal
among
allohsct
recipi
prompt
widespread
use
fluconazol
prophylaxi
earli
posttranspl
period
recent
data
prospect
antifung
therapi
path
allianc
registri
howev
report
incid
invas
candidiasi
allohsct
recipi
matchedrel
matchedunrel
donor
respect
candida
albican
account
half
episod
invas
candidiasi
hsct
recipi
invas
candidiasi
caus
azoleresist
candida
speci
c
glabrata
c
krusei
increas
sinc
may
reflect
routin
use
fluconazol
prophylaxi
invas
candidiasi
allohsct
recipi
commonli
present
fungemia
hepatosplen
candidiasi
candidemia
occur
approxim
hsct
recipi
may
accompani
sepsi
discreet
palpabl
vasculit
rash
andor
endorgan
involv
includ
limit
mening
endophthalm
endocard
contrast
hepatosplen
candidiasi
chronic
dissemin
candidiasi
result
invas
candida
speci
portal
vasculatur
subsequ
seed
liver
andor
spleen
period
neutropenia
exact
incid
hepatosplen
candidiasi
remain
unknown
one
autopsi
studi
identifi
hepat
candid
infect
hsct
recipi
patient
typic
present
fever
elev
alkalin
phosphatas
level
follow
neutrophil
recoveri
blood
cultur
tend
neg
set
comput
tomographi
abdomen
demonstr
multipl
lesion
liver
spleen
lesion
decreas
size
recurr
neutropenia
indic
hepatosplen
candidiasi
result
system
inflammatori
respons
biopsi
requir
definit
diagnosi
especi
ifi
malign
result
similar
clinic
syndrom
diagnosi
invas
candidiasi
remain
challeng
particularli
convent
blood
cultur
may
sensit
deep
fungal
infect
newer
diagnost
assay
includ
betadglucan
test
detect
betaglucan
cell
wall
mold
yeast
except
zygomycet
cryptococci
may
valuabl
diagnosi
invas
candidiasi
one
recent
studi
demonstr
sensit
specif
respect
assay
mannan
antigen
antibodi
candtec
candida
antigen
assay
demonstr
lower
sensit
betadglucan
assay
respect
given
preval
azoleresist
candida
speci
neutropen
patient
particularli
c
glabrata
c
krusei
manag
invas
candidiasi
allohsct
recipi
includ
amphotericin
b
echinocandin
caspofungin
micafungin
anidulafungin
sever
studi
demonstr
compar
efficaci
antifung
class
howev
echinocandin
associ
favor
toxic
profil
voriconazol
may
use
situat
addit
mold
coverag
desir
howev
sinc
voriconazol
resist
seen
candida
infect
solid
organ
hsct
recipi
agent
use
unless
suscept
isol
confirm
major
case
hepatosplen
candidiasi
caus
c
albican
clinic
stabl
patient
may
receiv
fluconazol
acut
ill
relaps
diseas
receiv
week
induct
liposom
amphotericin
b
echinocandin
follow
fluconazol
durat
therapi
hepatosplen
candidiasi
depend
upon
resolut
viscer
lesion
typic
month
chronic
suppress
therapi
may
use
individu
high
risk
recurr
includ
gvhd
aspergillu
mold
ubiquit
environment
pathogen
hsct
recipi
high
risk
infect
organ
larg
acquir
via
inhal
conidia
inadequ
clear
set
immunosuppress
less
common
rout
infect
includ
invas
gastrointestin
tract
cutan
inocul
invas
aspergillosi
frequent
ifi
encount
among
allohsct
recipi
data
path
allianc
demonstr
incid
invas
aspergillosi
recipi
matchedrel
donor
matchedunrel
donor
transplant
respect
autolog
allohsct
recipi
risk
develop
invas
aspergillosi
prolong
neutropenia
well
gvhd
treatment
contribut
higher
incid
invas
aspergillosi
among
allohsct
recipi
onset
invas
aspergillosi
follow
hsct
occur
bimod
fashion
first
peak
note
within
first
day
transplant
correspond
period
neutropenia
second
peak
occur
postengraft
late
period
typic
defin
day
follow
transplant
tend
aris
set
acut
chronic
gvhd
age
associ
develop
invas
aspergillosi
time
follow
transplant
donor
recipi
polymorph
variou
tolllik
receptor
gene
regul
promot
plasminogen
specif
donor
haplotyp
contain
two
cosegreg
singl
nucleotid
polymorph
tolllik
receptor
gene
associ
develop
invas
aspergillosi
singl
nucleotid
polymorph
chemokin
ligand
gene
also
demonstr
reduc
dendrit
cell
express
expos
aspergillu
germl
polymorph
also
associ
invas
aspergillosi
follow
allohsct
hematolog
malign
chronic
myelogen
leukemia
chronic
phase
well
aplast
anemia
myelodysplast
syndrom
mismatch
donor
use
cord
blood
summer
season
lack
laminar
air
flow
local
build
construct
identifi
risk
factor
invas
aspergillosi
earli
posttranspl
period
risk
invas
aspergillosi
late
posttranspl
period
increas
set
underli
multipl
myeloma
use
tcelldeplet
stem
cell
product
neutropenia
lymphopenia
use
corticosteroid
cmv
diseas
respiratori
viru
infect
gvhd
gvhd
cmv
diseas
major
risk
factor
develop
invas
aspergillosi
month
transplant
contribut
gvhd
risk
invas
aspergillosi
highlight
fact
condit
regimen
appear
impact
incid
invas
fungal
infect
period
neutropenia
shorter
incid
earli
invas
aspergillosi
less
nonmyeloabl
hsct
recipi
group
remain
highest
risk
late
posttranspl
period
conjunct
gvhd
aspergillu
fumigatu
commonli
isol
speci
associ
invas
aspergillosi
allogen
hsct
recipi
infect
niger
flavu
terreu
less
frequent
encount
lung
repres
commonli
involv
site
infect
though
patient
may
develop
sinus
cn
diseas
tracheobronch
clinic
present
may
variabl
frequent
includ
fever
cough
chest
pain
hemoptysi
andor
respiratori
failur
presenc
symptom
prompt
ct
chest
lung
lesion
surround
groundglass
halo
nodular
infiltr
cavit
highli
suggest
pulmonari
aspergillosi
howev
radiograph
find
variabl
allohsct
recipi
concomit
gvhd
includ
focal
infiltr
andor
bronchopneumonia
given
lack
specif
symptom
radiograph
find
prompt
microbiolog
diagnosi
via
bronchoscopi
pursu
diagnosi
invas
aspergillosi
may
also
facilit
use
aspergillu
galactomannan
assay
employ
doublesandwich
enzym
immunoassay
detect
galactomannan
compon
aspergillu
cell
wall
sensit
serum
galactomannan
assay
vari
studi
proven
clinic
use
diagnosi
invas
aspergillosi
monitor
clinic
respons
therapi
galactomannan
assay
bronchoalveolar
lavag
fluid
patient
hematolog
malign
hsct
recipi
demonstr
higher
sensit
bronchoalveolar
lavag
cultur
cytolog
serum
galactomannan
assay
import
caveat
use
galactomannan
test
includ
fals
neg
result
individu
receiv
concomit
antifung
fals
posit
result
children
patient
receiv
betalactam
particularli
piperacillintazobactam
crossreact
plasmalyt
betadglucan
test
detect
betaglucan
cell
wall
mold
yeast
except
zygomycet
cryptococci
may
also
valuabl
adjunct
screen
test
invas
aspergillosi
particularli
conjunct
galactomannan
assay
though
perform
characterist
betadglucan
assay
hsct
popul
yet
evalu
empir
therapi
suspect
invas
aspergillosi
includ
moldact
azol
amphotericin
b
use
echinocandin
also
entertain
though
agent
fungistat
rather
fungicid
diagnosi
invas
aspergillosi
confirm
primari
therapi
includ
voriconazol
patient
agent
associ
improv
clinic
outcom
surviv
rate
less
toxic
compar
amphotericin
b
voriconazol
also
prefer
therapi
aspergillu
tracheobronch
combin
therapi
echinocandin
either
amphotericin
b
moldact
azol
may
efficaci
voriconazol
alon
howev
particularli
salvag
therapi
durat
therapi
allogen
hsct
recipi
prolong
continu
least
immunosuppress
particularli
corticosteroid
complet
prevent
invas
aspergillosi
allogen
hsct
recipi
includ
use
higheffici
particul
air
hepa
filtrat
andor
laminar
flow
room
preengraft
period
addit
two
recent
studi
suggest
voriconazol
may
appropri
secondari
prophylaxi
prior
hsct
patient
previou
ia
mucor
rhizopu
speci
commonli
encount
zygomycet
clinic
practic
incid
recipi
matchedrel
matchedunrel
allohsct
respect
infect
organ
result
mucormycosi
occur
late
posttranspl
period
caus
devast
sinoorbit
cn
gastrointestin
diseas
well
cutan
lesion
fasciiti
among
hsct
recipi
risk
factor
zygomycosi
includ
hla
mismatch
prolong
neutropenia
corticosteroid
use
iron
overload
gvhd
addit
sever
studi
note
increas
number
zygomycosi
case
among
patient
receiv
voriconazol
either
prophylaxi
treatment
invas
aspergillosi
whether
reflect
azolerel
select
pressur
remain
unknown
fusarium
speci
environment
organ
caus
infrequ
sever
invas
fungal
infect
hsct
recipi
case
fusariosi
among
hsct
recipi
link
contamin
central
venou
cathet
hospit
water
suppli
risk
factor
fusariosi
includ
underli
multipl
myeloma
hla
mismatch
invas
aspergillosi
onset
fusariosi
occur
bimod
fashion
infect
earli
posttranspl
period
associ
prolong
neutropenia
late
infect
associ
tcell
deplet
corticosteroid
use
gvhd
infect
fusarium
speci
mimic
invas
aspergillosi
howev
patient
fusariosi
like
posit
blood
cultur
multipl
papular
ulcer
skin
lesion
compar
patient
invas
aspergillosi
scedosporium
apiospermum
scedosporium
prolifican
also
isol
hsct
recipi
diseas
spectrum
similar
invas
aspergillosi
risk
factor
scedosporium
infect
includ
prolong
neutropenia
gvhd
due
effect
prophylaxi
pcp
becom
rare
event
among
allohsct
recipi
retrospect
studi
show
incid
rate
pcp
usual
late
occurr
risk
factor
includ
treatment
gvhd
cessat
pcp
prophylaxi
despit
effect
treatment
mortal
high
infect
occur
earli
transplant
major
case
toxoplasmosi
allohsct
recipi
due
reactiv
latent
infect
unit
state
incid
toxoplasmosi
report
low
reflect
low
seropreval
popul
region
world
higher
seropreval
incid
rate
toxoplasmosi
predict
higher
diseas
usual
occur
first
month
transplant
besid
seroposit
main
risk
factor
reactiv
intensif
immunosuppress
due
gvhd
common
clinic
present
enceph
usual
present
focal
neurolog
deficit
extracn
form
toxoplasmosi
includ
pneumon
chorioretin
myocard
diagnosi
toxoplasmosi
manifest
requir
high
clinic
suspicion
toxoplasma
pcr
obtain
serum
tissu
csf
vitreou
fluid
firstlin
treatment
includ
extens
treatment
pyrimethamin
sulfadiazin
despit
best
effort
mortal
allohsct
recipi
remain
high
prophylaxi
usual
accomplish
trimethoprimsulfamethoxazol
strongyloid
stercorali
latent
infect
autohsct
recipi
previous
live
visit
endem
area
tropic
subtrop
region
worldwid
even
mani
decad
earlier
set
immunosuppress
parasit
life
cycl
acceler
caus
hyperinfect
dissemin
diseas
clinic
manifest
includ
intestin
obstruct
respiratori
failur
includ
alveolar
hemorrhag
bacteri
sepsi
mening
delay
diagnosi
infect
devast
carri
high
mortal
patient
endem
area
serolog
screen
treat
ivermectin
prior
transplant
like
solid
organ
transplant
recipi
allohsct
recipi
benefit
measur
aim
prevent
infecti
complic
posttranspl
period
includ
infect
control
practic
hospit
outpati
clinic
well
guidelin
prevent
opportunist
infect
cdcidsa
asbmt
publish
extens
evidencebas
infect
control
guidelin
includ
specif
practic
regard
room
ventil
isol
barrier
precaut
clean
hand
hygien
equip
disinfect
plant
patient
skin
oral
care
prevent
intravascular
catheterrel
infect
construct
renov
well
healthcar
worker
term
specif
infect
guidelin
cdc
publish
mani
organ
involv
reactiv
latent
infect
recipi
also
donorderiv
donor
recipi
univers
test
cmv
ebv
hiv
iii
htlv
iii
although
done
center
hepat
b
c
syphili
tuberculosi
donor
endem
countri
addit
recipi
test
hsv
iii
vzv
toxoplasma
potenti
donor
recipi
also
test
strongyloid
trypanosoma
cruzi
epidemiolog
risk
patient
evid
syphili
strongyloid
latent
tuberculosi
infect
treat
pretranspl
period
see
tabl
vaccin
import
compon
diseas
prevent
predict
declin
antibodi
titer
posttranspl
recommend
recipi
revaccin
postengraft
appropri
time
see
tabl
prophylaxi
posttranspl
period
usual
aim
common
predict
organ
discuss
strategi
prevent
cmv
beyond
scope
chapter
includ
either
preemptiv
treatment
case
cmv
viremia
univers
prophylaxi
risk
cmv
reactiv
recipi
risk
cmv
receiv
acyclovir
hsv
prophylaxi
pcp
toxoplasma
prophylaxi
accomplish
sulfamethoxazoletrimethoprim
month
although
practic
vari
take
consider
myelosuppress
effect
